Primary immune-mediated haemolytic anaemia: a retrospective long-term study in 61 dogs.
IMHA
canine
haemolysis
Journal
Australian veterinary journal
ISSN: 1751-0813
Titre abrégé: Aust Vet J
Pays: England
ID NLM: 0370616
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
07
04
2019
revised:
16
07
2019
accepted:
22
07
2019
pubmed:
28
8
2019
medline:
9
1
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
The objective of this study is to describe the course of disease of dogs with primary immune-mediated haemolytic anaemia (pIMHA) with an observation period longer than 90 days in regard to clinical signs, laboratory results and treatment response. Clinical records between January 2003 and December 2011 were reviewed. Diagnosis of pIMHA was based on the presence of haemolytic anaemia with a packed cell volume of <0.35 L/L, a positive Coombs' test and/or erythrocyte agglutination, spherocytosis and exclusion of an underlying disease. Included were dogs which could be monitored for more than 90 days after initial presentation. Sixty-one dogs with pIMHA were included. The initial packed cell volume ranged from 0.08 to 0.30 L/L (median 0.16). Immunosuppressive treatment included prednisolone in all the cases; 32 dogs successively received cyclosporine (28), cyclophosphamide (5), leflunomide (2) or human intravenous immunoglobulins (2) in addition. In 33/61 dogs, the drugs were discontinued 67-3372 days (median 334) after beginning of therapy; in 28 dogs, the drug dosage was reduced, but not discontinued until the end of the study. Three dogs developed immune-mediated thrombocytopenia (days 132, 156 and 680). The observation period ranged from 96 to 4147 days (median 628). A total of 22.9% (14/61) of the dogs developed a relapse after 94-3972 days (median 517). Five dogs were euthanased due to a relapse after 96-1188 days (median 628). Long-term prognosis in dogs with pIMHA is favourable. However, a relapse can occur after many years. Relapse was the most common cause of death in dogs with pIMHA that survive more than 90 days.
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-489Informations de copyright
© 2019 Australian Veterinary Association.
Références
Day MJ. Immune-mediated haemolytic anaemia. In: Day MJ, Kohn B, editors. BSAVA manual of canine and feline haematology and transfusion medicine. 2nd edn. British Small Animal Veterinary Association, Gloucester, 2012;59-73.
Burgess K, Moore A, Rand W et al. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000;14:456-462.
Piek CJ Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research. Vet Q 2011;31:129-141.
Piek CJ, Junius G, Dekker A et al. Idiopathic immune-mediated hemolyic anemia: treatment, outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008;22:366-373.
Griebsch C, Arndt G, Raila J et al. C-reactive protein concentration in dogs with primary immune-mediated hemolytic anemia. Vet Clin Pathol 2009;38:421-425.
Piek CJ, van Spil WE, Junius G et al. Lack of evidence of a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic anaemia: a retrospective cohort study. BMC Vet Res 2011;7:15-23.
Scott-Moncrieff JC, Treadwell NG, McCullough SM et al. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp 2001;37:220-227.
McManus PM, Craig LE Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 2001;218:1308-1313.
Carr AP, Pancierca DL, Kidd L Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 2002;16:504-509.
Weinkle TK, Center SA, Randolph JF et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005;226:1869-1880.
Ishihara M, Fujino Y, Setoguchi A et al. Evaluation of prognostic factors and establishment of a prognostic scoring system for canine primary immune-mediated hemolytic anemia. J Vet Med Sci 2009;72:465-470.
Kjelgaard-Hansen M, Goggs R, Wiinberg B et al. Use of serum concentration if interleukin-18 and monocyte chemoattractant protein-1 as prognostic indicators in primary immune-mediated hemolytic anemia. J Vet Intern Med 2011;25:76-82.
Goggs R, Dennis SG, Di Bella A et al. Predicting outcome in dogs with primary immune-mediated hemolytic anemia: results of a multicenter case registry. J Vet Intern Med 2015;29:1603-1610.
Swann JW, Skelly BJ Evaluation of immunosuppressive regimens for immune-mediated haemolytic anaemia: a retrospective study of 42 dogs. J Small Anim Pract 2011;52:353-358.
Reimer ME, Troy GC, Warnick LD Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999;35:384-391.
Weiss DH Uniform evaluation and semiquantitative reporting of hematologic data in veterinary laboratories. Vet Clin Pathol 1984;13:27-31.
Weiss DH, Tvedten H. Erythrocytes disorders. In: Tvedten H, editor. Small animal clinical diagnosis by laboratory methods. 4th edn. Elsevier Saunders, St. Louis, 2004;38-62.
Engelbrecht R, Kohn B, Leipold W et al. Klinische Befunde, Diagnostik und Behandlungserfolge bei der primären und sekundären immunhämolytischen Anämie beim Hund. Kleintierprax 2002;47:265-278.
Piek CJ. Immune-mediated hemolytic anemias and other regenerative anemias. In: Ettinger SJ, Feldman EC, Cote E, editors. Textbook of veterinary internal medicine. 8th edn. Elsevier Saunders, St. Louis, 2017;829-837.
Wang A, Smith JR, Creevy KE Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil ad glucocorticoids: 30 cases (2007-2011). J Small Anim Pract 2013;54:399-404.
Kennedy LJ, Barnes A, Ollier WER et al. Association of a common dog leucocyte antigen class II haplotype with canine primary immune-mediated haemolytic anaemia. Tissue Antigens 2006;68:502-508.
Friedenberg SG, Buhrman G, Chdid L et al. Evaluation of a DLA-79 allele associated with multiple immune-mediated diseases in dogs. Immunogenetics 2016;68:205-217.
Day MJ. Autoimmunity and autoimmune disease. In: Day MJ, Schultz RD, editors. Veterinary immunology. Principles and practice. 2nd edn. CRC Press, London, 2014;187-199.
Behrend EN, Kemppainen RJ Glucocorticoid therapy. Pharmacology, indications, and complications. Vet Clin North Am Small Anim Pract 1997;27:187-213.
Ohta H, Morita T, Yokoyama N et al. Serial measurement of pancreatic lipase immunoreactivity concentration in dogs with immune-mediated disease treated with prednisolone. J Small Anim Pract 2017;58:342-347.
Steiner JM, Teague SR, Lees GE et al. Stability of canine pancreatic lipase immunoreactivity concentration in serum samples and effects of long-term administration of prednisone to dogs on serum canine pancreatic lipase immunoreactivity concentrations. Am J Vet Res 2009;70:1001-1005.
Mansfield C Acute pancreatitis in dogs: advances in understanding, diagnostics, and treatment. Top Companion Anim Med 2012;27:123-132.
Plumb DC. In: Plumb DC, editor. Plumb's veterinary drug handbook. 8th edn. Wiley Blackwell, Iowa, 2015;99-101.
Marks SL, Kook PH, Papich MG et al. ACVIM consensus statement: Support for rational administration of gastrointestinal protectant to dogs and cats. J Vet Intern Med 2018;32:1823-1840.
Peterson AL, Torres SM, Rendahl A et al. Frequency of urinary tract infection in dogs with inflammatory skin disorders treated with ciclosporin alone or in combination with glucocorticoid therapy: a retrospective study. Vet Dermatol 2012;23:201-206.
Torres SMF, Diaz SF, Nogueira SA et al. Frequency of urinary tract infection among dogs with pruritic disorders receiving long-term glucocorticoid treatment. J Am Vet Med Assoc 2005;227:239-243.
Klein MK, Dow SW, Rosychuk RA Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 1989;195:246-250.
Johnson LR, Lappin MR, Baker DC Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 1999;13:338-345.
Feldman BF, Rasedee A, Feldman EC Haemostatic abnormalities in canine Cushing's syndrome. Res Vet Sci 1986;41:228-230.
AL O'K, Grant DC, Panciera DL et al. Effects of oral prednisone administration with or without ultralow-dose acetylsalicylic acid on coagulation parameters in healthy dogs. Am J Vet Res 2012;73:1569-1576.
Goggs R, Brainard BM, Blais MC et al. American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE) guidelines: Small animal. J Vet Emerg Crit Care 2019;29:12-36.
Swann JW, Garden OA, Fellman CL et al. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. J Vet Intern Med 2019;33:1141-1172.